Premium
The role of programmed cell death‐1 (PD‐1) and its ligands in pediatric cancer
Author(s) -
van Dam Laura S.,
de Zwart Verena M.,
MeyerWentrup Friederike A.G.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25284
Subject(s) - medicine , blockade , pd l1 , immune checkpoint , immune system , programmed cell death , antibody , cancer , biomarker , cancer research , blocking antibody , nivolumab , immunotherapy , immunology , receptor , apoptosis , biology , biochemistry
Abstract Programmed cell death‐1 (PD‐1) and its ligands, PD‐L1 and PD‐L2 maintain self‐tolerance and modulate physiological immune responses. Recently, targeting the PD‐1/PD‐L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD‐L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD‐1 function in the immune system to then focus on PD‐1 mediated tumor immune escape. Pediatr Blood Cancer 2015;62:190–197. © 2014 Wiley Periodicals, Inc.